Online Program

Impacts of big data velocity on quality healthcare decision-making in underserved populations

Monday, November 4, 2013 : 8:50 a.m. - 9:10 a.m.

Lyndsay Bloomfield, BS, DC, Enterprise Internet Solutions, State Farm, Bloomington, IL
Leveraging big data analytics in healthcare decision making requires vetting the risk of people, processes, and systems. Today, healthcare decision making is poorly organized, inefficient, and largely siloed in operation, resulting in a disproportional disadvantage in quality of care for underserved populations. Big data attributes include volume, velocity, and variety. The purpose of this paper is to highlight how big data velocity will positively impact the quality of healthcare decision making, particularly in underserved populations. The ensuing paper presents information on how integrating procedural data with outside data sources will drive better healthcare decisions, support identification of critical and emerging healthcare needs, and executing on patient specific best practices through decreased data fragmentation. Areas for continued research are proposed including the role of governance in early onboarding and socialization, as well as metrics in big data change adoption.

Learning Areas:

Communication and informatics
Other professions or practice related to public health

Learning Objectives:
Define three attributes of big data. Discuss how current utilization of big data impacts underserved populations. Describe big data’s role in identifying healthcare needs, supporting patient specific best practices, and driving quality healthcare decisions.

Keyword(s): Information Technology, Technology

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I currently work with data as a Senior Analyst in Enterprise Internet Solutions at State Farm.
Any relevant financial relationships? Yes

Name of Organization Clinical/Research Area Type of relationship
State Farm None-Employment Employment (includes retainer)

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.